Aman U. Buzdar
The University of Texas MD Anderson Cancer Center · 672 works · 52,550 citations · h-index 115
Top works
- Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
- Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
- THE IMPACT OF NATIONAL CANCER ACT
- Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy
- Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.
- Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma
- Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer
- Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer
- Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
- Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
- Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy
- Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
- Pathological assessment of response to induction chemotherapy in breast cancer.
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
- Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer
- Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
- Multimodal treatment of locoregionally advanced breast cancer
- Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma